Progyny, Inc. Selling and Marketing Expense
Progyny, Inc. (PGNY) reported Selling and Marketing Expense of $18.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-07
- Progyny, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $18.07M, a 1.80% decline year-over-year.
- Progyny, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $16.88M, a 5.07% decline year-over-year.
- Progyny, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $17.99M, a 15.18% increase year-over-year.
- Progyny, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $17.93M, a 8.98% increase year-over-year.
- Progyny, Inc. selling and marketing expense for fiscal 2025 was $72.11M, a 12.77% increase from fiscal 2024.
- Progyny, Inc. selling and marketing expense for fiscal 2024 was $63.95M, a 7.50% increase from fiscal 2023.
- Progyny, Inc. selling and marketing expense for fiscal 2023 was $59.49M, a 30.29% increase from fiscal 2022.
- Progyny, Inc. selling and marketing expense for fiscal 2022 was $45.66M, a 126.26% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.07M 10-Q · filed 2026-08-07 | $34.96M 10-Q · filed 2026-08-07 | $52.95M derived: sum of 3 quarters · filed 2026-08-07 | $70.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $16.88M 10-Q · filed 2026-05-08 | $34.87M derived: sum of 2 quarters · filed 2026-05-08 | $52.81M derived: sum of 3 quarters · filed 2026-05-08 | $71.21M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $17.99M 10-K · filed 2026-02-27 | $35.92M derived: sum of 2 quarters · filed 2026-02-27 | $54.33M derived: sum of 3 quarters · filed 2026-08-07 | $72.11M 10-K · filed 2026-02-27 |
| 2025-09-30 | $17.93M 10-K · filed 2026-02-27 | $36.34M derived: sum of 2 quarters · filed 2026-08-07 | $54.13M 10-Q · filed 2025-11-07 | $69.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $18.41M 10-Q · filed 2026-08-07 | $36.19M 10-Q · filed 2026-08-07 | $51.81M derived: sum of 3 quarters · filed 2026-08-07 | $68.26M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $17.79M 10-Q · filed 2026-05-08 | $33.40M derived: sum of 2 quarters · filed 2026-05-08 | $49.86M derived: sum of 3 quarters · filed 2026-05-08 | $66.28M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $15.62M 10-K · filed 2026-02-27 | $32.07M derived: sum of 2 quarters · filed 2026-02-27 | $48.49M derived: sum of 3 quarters · filed 2026-02-27 | $63.95M 10-K · filed 2026-02-27 |
| 2024-09-30 | $16.46M 10-K · filed 2026-02-27 | $32.88M derived: sum of 2 quarters · filed 2026-02-27 | $48.33M 10-Q · filed 2025-11-07 | $63.24M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $16.42M 10-K · filed 2026-02-27 | $31.88M 10-Q · filed 2025-08-08 | $46.79M derived: sum of 3 quarters · filed 2026-02-27 | $61.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $15.45M 10-K · filed 2026-02-27 | $30.36M derived: sum of 2 quarters · filed 2026-02-27 | $45.28M derived: sum of 3 quarters · filed 2026-02-27 | $60.66M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $14.91M 10-K · filed 2025-03-03 | $29.82M derived: sum of 2 quarters · filed 2025-03-03 | $45.21M derived: sum of 3 quarters · filed 2025-03-03 | $59.49M 10-K · filed 2026-02-27 |
| 2023-09-30 | $14.91M 10-K · filed 2025-03-03 | $30.30M derived: sum of 2 quarters · filed 2025-03-03 | $44.58M 10-Q · filed 2024-11-12 | $57.56M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $15.38M 10-K · filed 2025-03-03 | $29.67M 10-Q · filed 2024-08-07 | $42.65M derived: sum of 3 quarters · filed 2025-03-03 | $53.81M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $14.28M 10-K · filed 2025-03-03 | $27.26M derived: sum of 2 quarters · filed 2025-03-03 | $38.43M derived: sum of 3 quarters · filed 2025-03-03 | $49.92M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $12.98M 10-K · filed 2024-02-29 | $24.15M derived: sum of 2 quarters · filed 2024-02-29 | $35.64M derived: sum of 3 quarters · filed 2024-02-29 | $45.66M 10-K · filed 2025-03-03 |
| 2022-09-30 | $11.17M 10-K · filed 2024-02-29 | $22.66M derived: sum of 2 quarters · filed 2024-02-29 | $32.68M 10-Q · filed 2023-11-08 | $40.37M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $11.50M 10-K · filed 2024-02-29 | $21.51M 10-Q · filed 2023-08-04 | $29.21M derived: sum of 3 quarters · filed 2024-02-29 | $33.65M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $10.02M 10-K · filed 2024-02-29 | $17.71M derived: sum of 2 quarters · filed 2024-02-29 | $22.15M derived: sum of 3 quarters · filed 2024-02-29 | $26.18M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $7.70M 10-K · filed 2023-03-01 | $12.14M derived: sum of 2 quarters · filed 2023-03-01 | $16.16M derived: sum of 3 quarters · filed 2023-03-01 | $20.18M 10-K · filed 2024-02-29 |
| 2021-09-30 | $4.44M 10-K · filed 2023-03-01 | $8.47M derived: sum of 2 quarters · filed 2023-03-01 | $12.48M 10-Q · filed 2022-11-04 | $17.26M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $4.03M 10-K · filed 2023-03-01 | $8.04M 10-Q · filed 2022-08-05 | $12.82M derived: sum of 3 quarters · filed 2023-03-01 | $16.17M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $4.01M 10-K · filed 2023-03-01 | $8.79M derived: sum of 2 quarters · filed 2023-03-01 | $12.14M derived: sum of 3 quarters · filed 2023-03-01 | $15.75M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $4.78M 10-K · filed 2022-03-01 | $8.13M derived: sum of 2 quarters · filed 2022-03-01 | $11.74M derived: sum of 3 quarters · filed 2022-03-01 | $15.01M 10-K · filed 2023-03-01 |
| 2020-09-30 | $3.35M 10-K · filed 2022-03-01 | $6.96M derived: sum of 2 quarters · filed 2022-03-01 | $10.23M 10-Q · filed 2021-11-08 | $13.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $3.61M 10-K · filed 2022-03-01 | $6.88M 10-Q · filed 2021-08-06 | $10.13M derived: sum of 3 quarters · filed 2022-03-01 | $13.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.27M 10-K · filed 2022-03-01 | $6.52M derived: sum of 2 quarters · filed 2022-03-01 | $9.71M derived: sum of 3 quarters · filed 2022-03-01 | $12.82M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.25M 10-K · filed 2021-03-01 | $6.44M derived: sum of 2 quarters · filed 2021-03-01 | $9.55M derived: sum of 3 quarters · filed 2021-03-01 | $11.90M 10-K · filed 2022-03-01 |
| 2019-09-30 | $3.18M 10-K · filed 2021-03-01 | $6.30M derived: sum of 2 quarters · filed 2021-03-01 | $8.65M 10-Q · filed 2020-11-06 | $10.79M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.12M 10-K · filed 2021-03-01 | $5.46M 10-Q · filed 2020-08-07 | $7.61M derived: sum of 3 quarters · filed 2021-03-01 | $9.25M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $2.35M 10-K · filed 2021-03-01 | $4.49M derived: sum of 2 quarters · filed 2021-03-01 | $6.14M derived: sum of 3 quarters · filed 2021-03-01 | $7.87M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.14M 10-K · filed 2020-03-10 | $3.79M derived: sum of 2 quarters · filed 2020-03-10 | $5.52M derived: sum of 3 quarters · filed 2020-03-10 | $7.29M 10-K · filed 2021-03-01 |
| 2018-09-30 | $1.65M 10-K · filed 2020-03-10 | $3.38M derived: sum of 2 quarters · filed 2020-03-10 | $5.14M 10-Q · filed 2019-12-06 | |
| 2018-06-30 | $1.73M 10-K · filed 2020-03-10 | $3.49M derived: sum of 2 quarters · filed 2020-03-10 | ||
| 2018-03-31 | $1.76M 10-K · filed 2020-03-10 | |||
| 2017-12-31 | $4.26M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |